SEC Comment Letter for Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) (CRBP) — Nov 18, 2015
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)
Date: Nov. 18, 2015 · CIK: 0001595097 · Accession: 0000000000-15-054612
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-207936
Letter
Mail Stop 4720 November 1 8, 2015 Via E -mail Yuval Cohen Chief Executive Officer Corbus Pharmaceuticals Holdings, Inc. 100 River Ridge Drive Norwood, MA 02062
Re: Corbus Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 Filed November 10 , 2015 File No. 333-207936
Dear Mr. Cohen :
This is to advise you that we have not reviewed and will not review your registration statement .
We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Act of 193 3 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.
In the event you request acceleration of the effective date of the pending regist ration statement , please provide a written statement from the company acknowledging that:
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure i n the filing; and
the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Yuval Cohen Corbus Pharmaceuticals Holdings, Inc. November 1 8, 2015 Page 2
Please refer to Rules 460 an d 461 regarding requests for acceleration . We will consider a written request for acceleration of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are aware of their respective responsibilitie s under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the registered securities .
Please contact Scot Foley at (202) 551 -3383 or me a t (202) 551 -3675 with any questions.
Sincerely,
/s/ Suzanne Hayes
Show Raw Text
Mail Stop 4720 November 1 8, 2015 Via E -mail Yuval Cohen Chief Executive Officer Corbus Pharmaceuticals Holdings, Inc. 100 River Ridge Drive Norwood, MA 02062 Re: Corbus Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 Filed November 10 , 2015 File No. 333-207936 Dear Mr. Cohen : This is to advise you that we have not reviewed and will not review your registration statement . We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Act of 193 3 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In the event you request acceleration of the effective date of the pending regist ration statement , please provide a written statement from the company acknowledging that: should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure i n the filing; and the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Yuval Cohen Corbus Pharmaceuticals Holdings, Inc. November 1 8, 2015 Page 2 Please refer to Rules 460 an d 461 regarding requests for acceleration . We will consider a written request for acceleration of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are aware of their respective responsibilitie s under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the registered securities . Please contact Scot Foley at (202) 551 -3383 or me a t (202) 551 -3675 with any questions. Sincerely, /s/ Suzanne Hayes Suzanne Hayes Assistant Director cc: Michael J. Lerner, Esq. Steven M. Skolnick, Esq. Lowenstein Sandler LLP 1251 Avenue of the Americas New York, New York 10020